IGGA
CORT icon

Iron Gate Global Advisors’s Corcept Therapeutics CORT Stock Holding History

Iron Gate Global Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
+3,500
New +$211K 0.03% 79
2025
Q4 		– Sell
-3,500
Closed -$292K – 105
2025
Q3 		$292K Hold
3,500
– – 0.03% 82
2025
Q2 		$257K Hold
3,500
– – 0.03% 72
2025
Q1 		$400K Buy
+3,500
New +$213K 0.06% 58

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iron Gate Global Advisors's CORT Position: Q2 2026 in Review

Iron Gate Global Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,500 shares worth $304K. The stake represents 0.03% of the portfolio and ranks #79 among its holdings. This is a return to the name: Iron Gate Global Advisors previously reported a position in CORT as recently as Q3 2025.

Iron Gate Global Advisors first reported a position in CORT in Q1 2025 and has held it in 4 quarters since. The position peaked at $400K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Iron Gate Global Advisors held 3,500 shares of Corcept Therapeutics worth $304K as of Q2 2026.
  • Corcept Therapeutics was a new Iron Gate Global Advisors position in Q2 2026.
  • Corcept Therapeutics made up 0.03% of Iron Gate Global Advisors's portfolio in Q2 2026, its #79 holding.
  • Iron Gate Global Advisors first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Iron Gate Global Advisors's Corcept Therapeutics position peaked at $400K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Iron Gate Global Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.